repurpos
exist
drug
time
option
cope
predict
therapeut
candid
could
revers
gene
express
coronavirusinfect
host
cell
thirteen
express
signatur
comput
variou
experiment
condit
preclin
model
could
revers
compound
known
effect
sarsor
merscov
well
drug
candid
recent
shown
effect
select
ten
novel
candid
evalu
vitro
efficaci
infect
four
compound
bortezomib
dactolisib
alvocidib
methotrex
inhibit
format
viru
infectioninduc
cytopath
effect
vero
cell
yet
concentr
seem
toxic
cell
well
evalu
permiss
cell
predict
toxic
need
optim
minim
antivir
activ
cytotox
respect
comput
approach
potenti
rapidli
ration
identifi
drug
candid
sinc
earli
decemb
newli
emerg
infect
almost
million
peopl
global
unit
state
confirm
case
increas
dozen
almost
within
two
week
number
rapidli
grew
within
one
month
among
patient
suffer
sever
acut
respiratori
distress
syndrom
ard
approxim
die
acut
respiratori
failur
acut
cardiac
injuri
secondari
infect
seriou
complic
organ
declar
rapidli
spread
highli
pathogen
first
global
public
health
emerg
pandem
infect
continu
endang
live
effect
therapeut
urgent
need
repurpos
exist
drug
could
effici
time
mean
identifi
drug
activ
coronaviru
repurpos
drug
lopinavirritonavir
baricitinib
remdesivir
chloroquin
current
clinic
investig
drug
expect
target
key
step
viral
entri
specif
protein
involv
viral
replic
includ
viral
proteas
addit
viral
replic
viral
pathogen
associ
molecular
pattern
pamp
eg
immun
dysfunct
endoplasm
reticulum
stress
figur
could
target
improv
clinic
outcom
pampsmedi
signal
pathway
attract
drug
target
allevi
diseas
caus
human
pathogen
therefor
effect
target
pathway
stop
progress
ard
caus
might
save
live
independ
infect
age
adult
popul
ard
associ
mortal
rate
thu
method
unbias
search
new
drug
candid
larg
drug
librari
could
uncov
agent
potenti
arrest
infect
amelior
effect
accomplish
sought
target
infectioninduc
gene
host
cell
hope
mitig
diseas
progress
allevi
symptom
other
util
systemsbas
approach
employ
gene
express
profil
diseas
sampl
druginduc
gene
express
profil
cell
line
discov
new
therapeut
candid
diseas
essenti
idea
identifi
drug
revers
diseas
gene
express
signatur
suppress
overexpress
diseas
gene
activ
repress
gene
figur
diseas
signatur
defin
list
differenti
express
gene
diseas
sampl
normal
control
sampl
recent
found
revers
gene
express
name
srge
correl
drug
efficaci
cancer
demonstr
feasibl
appli
approach
predict
drug
candid
diseas
includ
viral
infect
util
approach
drug
discoveri
first
need
collect
virusrel
host
gene
express
profil
avail
time
write
given
high
genom
similar
sarscov
merscov
reason
exist
host
gene
express
profil
sampl
infect
sarsor
merscov
could
approxim
infect
verifi
assumpt
compil
virusinduc
signatur
enrichr
geo
tabl
use
establish
pipelin
score
drug
repurpos
librari
regard
revers
signatur
gene
express
cluster
signatur
base
drug
predict
score
suggest
signatur
deriv
viru
viru
famili
similar
experiment
model
tend
cluster
togeth
figur
exampl
cluster
includ
one
signatur
deriv
primari
human
microvascular
endotheli
cell
merscov
infect
studi
id
anoth
deriv
melanoma
cell
mice
seven
day
sarscov
infect
studi
id
addit
spearman
correl
coeffici
vitro
drug
efficaci
data
half
maxim
effect
concentr
sarscov
merscov
figur
cluster
correl
result
suggest
drug
predict
base
signatur
relat
sarscov
merscov
could
also
appli
therefor
develop
pipelin
repurpos
exist
drug
merscov
sarscov
experiment
evalu
drug
figur
databas
good
candid
activ
repress
biolog
process
inhibit
upregul
process
b
correl
publish
antivir
activ
drug
transform
valu
moll
mersand
sarscov
c
studi
workflow
includ
creation
diseas
signatur
predict
drug
candid
select
final
drug
list
vitro
valid
one
diseas
signatur
compos
differenti
express
gene
comparison
led
one
drug
predict
list
signatur
result
predict
list
known
posit
drug
enrich
top
consid
valid
signatur
dysregul
pathway
sar
infect
compar
lung
e
enrich
top
six
dysregul
pathway
primari
human
microvascular
endotheli
cell
merscov
infect
left
mock
right
one
studi
select
e
respect
dysregul
pathway
dynam
studi
avail
supplementari
materi
figur
extend
data
total
sampl
infect
either
mersor
sarscov
differ
model
eg
cell
line
mous
model
across
multipl
time
point
public
repositori
use
identif
diseas
signatur
tabl
studi
total
express
profil
creat
use
either
microarray
rnasequenc
depend
profil
platform
data
process
signatur
creation
method
comparison
comput
diseas
signatur
character
infect
statu
follow
predict
drug
may
activ
could
directli
evalu
qualiti
patholog
relev
diseas
signatur
turn
valid
action
use
drug
posit
vitro
merssar
test
posit
drug
total
valu
tabl
among
merscov
sarscov
infect
signatur
signatur
led
drug
list
posit
drug
highli
enrich
top
extend
data
moreov
drug
significantli
correl
srge
figur
figur
contrast
infect
signatur
nt
observ
signific
enrich
anticoronaviru
posit
drug
extend
data
recent
clinic
data
suggest
combin
two
drug
lopinavirritonavir
present
clinic
benefit
patient
coronaviru
drug
profil
linc
individu
howev
none
could
induc
substanti
gene
express
chang
absolut
z
score
concentr
cancer
cell
line
therefor
neither
predict
hit
next
found
anoth
dataset
heparg
cell
treat
ritonavir
differ
concentr
nm
observ
ritonavir
could
revers
nearli
diseas
signatur
high
concentr
ie
figur
togeth
reason
highli
rank
drug
greater
neg
srge
valid
comparison
could
new
therapeut
candid
obtain
final
drug
predict
trivial
merg
diseas
signatur
deriv
differ
platform
biolog
condit
instead
merg
calcul
consensu
score
drug
predict
list
deriv
individu
valid
diseas
signatur
took
median
rank
across
multipl
comparison
drug
rank
base
median
rank
extend
data
mechan
action
moa
enrich
analysi
final
rank
drug
list
reveal
signific
drug
class
includ
cdk
inhibitor
mtor
inhibitor
pathway
inhibitor
figur
late
jeon
et
al
test
antivir
efficaci
fdaapprov
drug
among
posit
drug
overlap
screen
librari
drug
also
significantli
enrich
top
predict
figur
p
valid
predict
interestingli
three
antiparasit
drug
pyrvinium
ivermectin
niclosamid
rank
among
top
ivermectin
niclosamid
could
inhibit
replic
vitro
pyrvinium
niclosamid
effect
mer
sar
manual
inspect
top
candid
select
ten
repres
candid
accord
revers
score
figur
clinic
applic
moa
administr
rout
safeti
tabl
final
evalu
cytotox
abil
prevent
cytopath
effect
cpe
vero
cell
line
tabl
instead
measur
use
stringent
criteria
requir
complet
prevent
cpe
observ
microcopi
six
propos
drug
show
less
minimum
concentr
could
complet
prevent
cpe
howev
five
present
unfavor
cytotox
effect
concentr
follow
confirmatori
experi
examin
efficaci
toxic
four
effect
drug
cpe
prevent
concentr
bortezomib
methotrex
alvocidib
well
chloroquin
drug
use
firstlin
treatment
none
predict
drug
could
complet
prevent
cpe
though
chloroquin
could
dose
figur
signatur
comparison
h
could
captur
biolog
viral
infect
thu
fail
recov
known
drug
find
also
reiter
challeng
choos
appropri
experiment
model
right
time
point
drug
treatment
develop
consensu
score
drug
base
potenc
revers
thirteen
signatur
predict
extern
valid
recent
drug
screen
obtain
total
sampl
sar
mer
relat
data
arrayexpress
gene
comput
rge
summar
rge
detail
elsewher
recent
implement
standalon
r
packag
neg
correl
mean
revers
relat
ritonavir
origin
develop
inhibitor
hiv
proteas
often
use
low
dose
proteas
inhibitor
boost
antivir
effect
analysi
suggest
ritonavir
could
revers
diseas
signatur
high
dose
process
compound
transcriptom
profil
categor
upand
downregul
gene
threshold
fold
chang
greater
less
respect
group
gene
submit
enrichr
http
amppharmmssmeduenrichr
comput
gene
ontolog
enrich
go
term
pvalu
less
adjust
pvalu
less
taken
signific
vero
cell
atcc
grown
eagl
minim
essenti
medium
emem
supplement
penicillin
unitsml
streptomycin
fetal
bovin
serum
fb
isol
rd
passag
vero
cell
origin
cdc
atlanta
materi
sequenc
confirm
use
throughout
studi
titer
viral
stock
tissu
cultur
infecti
dose
ml
experi
involv
use
infecti
viru
conduct
univers
texa
medic
branch
approv
biosafeti
level
laboratori
slightli
modifi
vero
standard
microneutr
assay
use
rapidli
evalu
analysi
conduct
r
python
program
languag
pheatmap
seaborn
packag
use
data
visual
student
ttest
perform
normal
distribut
data
wilcoxon
ranksum
test
use
type
data
comput
pvalu
author
declar
data
use
studi
avail
within
articl
supplementari
inform
file
specif
file
provid
correspond
author
upon
reason
request
code
avail
github
http
githubcombinchenlabwar
